Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00081575 |
To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.
Condition | Intervention | Phase |
---|---|---|
Community-Acquired Infections Bacterial Pneumonia Cross Infection |
Drug: Tigecycline Drug: Levofloxacin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Safety/Efficacy Study |
Official Title: | A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 3074A1-313 |
Study First Received: | April 15, 2004 |
Last Updated: | October 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00081575 |
Health Authority: | United States: Food and Drug Administration |
Bacterial Pneumonia |
Bacterial Infections Respiratory Tract Infections Respiratory Tract Diseases Tigecycline Lung Diseases |
Pneumonia, Bacterial Ofloxacin Community-Acquired Infections Pneumonia Cross Infection |
Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Infective Agents, Urinary |
Enzyme Inhibitors Renal Agents Infection Nucleic Acid Synthesis Inhibitors Pharmacologic Actions |